This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Merck Sharp & Dohme LLC, doing business as Merck, a major pharmaceutical manufacturer. The contract has a $2,993,341,000 ceiling value and a period of performance from April 1, 2021 through March 31, 2022.
The purpose of this IDC is to provide a range of standard pediatric vaccines required to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. Awarded vaccines include DTaP, DTaP/Hep B/IPV, DTaP-IPV, DTaP-IP-HiB, IPV, Hepatitis A, Hepatitis A&B, Hepatitis B, Hib, HPV, MMR, MCV4, PCV13, PPSV23, Rotavirus, Td, Tdap, Varicella, and MenB. The contract requires the vaccines to have a minimum 12-month shelf life and be manufactured under a current FDA license. Merck will ship the vaccines F.O.B. Destination to the 50 states and U.S. territories. This acquisition was conducted under FAR Part 12 for commercial items and did not involve any set-asides.
Generated 11/28/24, 9:05 AM